Indicated for: cancer
Route of administration: injectable / infusion
Substance: vincristine (antineoplastic agent)
ATC: L01CA02 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
This medicine may affect the nerves or nervous system.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Vincristine is a chemotherapy medication used for the treatment of various types of cancer, including acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Ewing's sarcoma. It belongs to the vinca alkaloid class and works by inhibiting microtubule formation, leading to the arrest of cell division and tumor cell death.
Vincristine is administered intravenously, usually once a week, and the dosage is adjusted based on body weight and patient response. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.
Common side effects include peripheral neuropathy, constipation, hair loss, nausea, and fatigue. In rare cases, severe adverse reactions such as liver function impairment or bone marrow depression may occur.
Vincristine is an essential component of many chemotherapy regimens, helping to reduce tumor size and improve survival rates in cancer patients.